Clinical Trial

A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
An open-label, randomized, comparative phase II study including patients with CLDN18.2-positive unresectable locally advanced gastric cancer. To evaluate the objective response rate (ORR) and progression-free survival (PFS) of IMC002 compared with investigator's choice of treatment (ICT) as third-line or later therapy in patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with positive CLDN18.2 expression.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-01.
Status change: Not Yet Recruiting → Recruiting 2025-10-21
Trial Details
NCT Number NCT07103668
Lead Sponsor Suzhou Immunofoco Biotechnology Co., Ltd
Conditions Gastric Adenocarcinoma
Enrollment 150 participants
Start Date 2025-08-06
Primary Completion 2027-05-31 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-10-23